Immutep Ltd · ASX:IMM
Immutep — Technical Presentation (April 2020)
7 slides from Immutep's technical presentation, Apr 27, 2020
Slide 1: Initial results from Phase II study TACTI-002 in NSCLC or head and neck cancer
Poster Board: 18 LB-394 Initial results from a Phase II study (TACTI-002) in Non- Small Cell Lung Cancer, or Head and Neck cancer patients receiving eftilagimod alpha (a soluble LAG-3 protein) and pembrolizumab 27th April 2020 Presenting Author: Martin Forster, University College London Hospitals NH
Slide 2: Eftilagimod alpha (efti): Innovative LAG-3 I-O Product Candidate
Eftilagimod alpha (efti) Innovative LAG-3 I-O Product Candidate MoA: Efti is a soluble LAG-3 protein targeting a subset of MHC class II on APC to mediate antigen presenting cell (APC) and then CD8 T-cell activation. Rationale: Efti activates APCs and leads to an increase in activated T cells which e
Slide 3: TACTI-002 Trial Design + Introduction
eftilagimod alpha TACTI-002 Trial Design + Introduction → Phase II, multi-national, open label, PD-L1 (central assessment) all comer trial → The study has a Simon's optimal two-stage design. During the first stage, N1 patients are recruited. Additional patients (N2) will be recruited for each part i
Slide 4: Results 1 – all parts stage 1: Exposure and Safety
eftilagimod alpha - TACTI-002 Results1 – all parts stage 1 Exposure and Safety Summary TEAEs occured in ≥10 % of pts (N=63 in total) Any Grade Grade 3 Grade 4 • In total 63 pts were enrolled until data cut-off1. Adverse event (PT) N (%) N (%) N (%) Recruitment is ongoing. • Pts received median 6 (ra
Slide 5: Baseline Characteristics + efficacy Part A - 1st line NSCLC
eftilagimod alpha - TACTI-002 Results1 - 1st line NSCLC (part A, stage 1) Baseline Characteristics + efficacy Part A* - 1st line NSCLC Best response: 100 • PD-L1 distribution as historically expected with 31 % of evaluable iUPD/iCPD best % change from baseline 75 iSD pts ≥ 50 % → PD-L1 all comer tri
Slide 6: Baseline Characteristics + efficacy Part C - 2nd line HNSCC
eftilagimod alpha - TACTI-002 Results1 – 2nd line HNSCC (part C, stage 1) Baseline Characteristics + efficacy Part C* - 2nd line HNSCC 100 Best response: • Median age 66, 94 % male, 47 % ECOG 1, different HNSCC iUPD/iCPD best % change from baseline subtypes -> typical 2nd line HNSCC population 75 iS
Slide 7: Authors and Affiliates
Poster Board: 18 LB-394 Authors: Forster M1, Felip E2, Doger B3, Majem M4, Carcereny E5, Bajaj P6, Clay T7, Krebs M8, Peguero J9, Roxburgh P10, Triebel F11 Affiliates: 1 - University College London Hospitals NHS Foundation, London, UK;2 - Vall d’ Hebron University Hospital, Barcelona, Spain; 3 - STA